Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma
Authors:
Open Access
- 28 November 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (65) , 109587-109595
Abstract
Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcomaKeywords
This publication has 32 references indexed in Scilit:
- Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant MelanomaPLOS ONE, 2013
- Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant LeukemiaPLOS ONE, 2013
- Identification of new possible targets for leukemia treatment by kinase activity profilingLeukemia & Lymphoma, 2010
- Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab TherapyCancer Research, 2010
- Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target DiscoveryCancer Research, 2009
- Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readoutMolecular Cancer Therapeutics, 2009
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapyNature Biotechnology, 2008
- Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer CellsClinical Cancer Research, 2008
- Use of comparative proteomics to identify potential resistance mechanisms in cancer treatmentCancer Treatment Reviews, 2007
- Proteins, drug targets and the mechanisms they control: the simple truth about complex networksNature Reviews Drug Discovery, 2007